Research Analysts’ Recent Ratings Updates for Tempus AI (TEM)

Several analysts have recently updated their ratings and price targets for Tempus AI (NASDAQ: TEM):

• 10/26/2026 – Tempus AI had its price target raised by HC Wainwright from $66.00 to $68.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Tempus AI had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.
• 10/23/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 10/14/2026 – Tempus AI had its price target raised by JPMorgan Chase & Co. from $45.00 to $70.00. They now have a “neutral” rating on the stock.
• 10/13/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/12/2026 – Tempus AI had its price target raised by Canaccord Genuity Group from $80.00 to $95.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Tempus AI had its price target raised by Guggenheim from $65.00 to $92.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Tempus AI was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group. They set a “neutral” rating and a $75.00 price target on the stock.
• 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group. They set a “neutral” rating and a $75.00 price target on the stock.
• 9/11/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/11/2026 – Tempus AI had its price target raised by HC Wainwright from $56.00 to $66.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Tempus AI is now covered by UBS Group. They set a “neutral” rating and a $70.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Roth Capital. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/2/2026 – Tempus AI was given a new $80.00 price target by Raymond James Financial.
• 9/2/2026 – Tempus AI is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
• 9/1/2026 – Tempus AI was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $76.00 price target on the stock, up from $56.00.

Insider Activity at Tempus AI

In other news, CFO James Rogers sold 26,313 shares of Tempus AI stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer directly owned 106,024 shares in the company, valued at $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the transaction, the executive vice president owned 146,067 shares in the company, valued at $7,246,383.87. This represents a 13.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,030,965 shares of company stock worth $69,882,564 over the last three months. 24.26% of the stock is currently owned by company insiders.

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.